undamentalytics Newsletter
Sign in

Adicet Bio, Inc. (ACET) stock

Add to watchlist

Add holding +

NASDAQ: ACET Nasdaq Biotechnology Next results ~November 5, 2026

Adicet Bio, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$9.5

Forward price-to-sales vs peers

Base case. Range ~$9.5–$36. Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative.

Price vs value

No Buy/Hold/Sell rating is issued: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Adicet Bio, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 1 selling3 purchases and 4 sales by directors and officers, last 12 monthsInsider trades
  • Funds31 adding, 15 cuttingOf 14 active managers that changed their stake, 11 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Current signal Share count rising (dilution): Diluted shares outstanding rose 83.5% year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Adicet Bio, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Results due soon. Results are expected around 4 November; the share price can move sharply on the day.
  • Share dilution. Diluted shares rose 83.5% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 75% and a beta of 2.2 against the S&P 500.
  • Short interest rising. Shares sold short rose 92% in a month to 5.6% of tradable shares.

Latest results

Earnings per share
-$1.99 against an average estimate of -$1.64: missed by 21.5%
Share reaction
-13.9% in the first session after the results on August 5, 2026, against -0.4% for the S&P 500
Next report
November 5, 2026; average EPS estimate -$1.58

Adicet Bio's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-6.4%
  • 1 week-18.8%
  • 1 month-50.8%
  • This year-62.0%
  • 1 year-73.3%
  • 5 years-97.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 5, 2026
Next results (est.)
November 4, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement
  3. Announcement
  4. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Adicet Bio, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Adicet Bio, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.32 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$9.5 ~$9.7–$36 Included, half weight
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$9.5 ~$9.5–$36 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Adicet Bio, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, after the close. Analysts expect revenue of $0 and EPS of −$1.58 (range −$2.05 to −$1.01) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$6.36 +63% — 0%
Next −$4.04 +37% $29m 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −28.3% on 90 days ago. In the last 30 days, 2 analysts raised Adicet Bio, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Adicet Bio, Inc., last 90 days
−$10.00 −$5.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$8.87 Current fiscal year, 60 days ago: −$8.80 Current fiscal year, 30 days ago: −$6.40 Current fiscal year, 7 days ago: −$6.36 Current fiscal year, Now: −$6.36 −$6.36 Next fiscal year, 90 days ago: −$4.19 Next fiscal year, 60 days ago: −$3.49 Next fiscal year, 30 days ago: −$3.95 Next fiscal year, 7 days ago: −$4.04 Next fiscal year, Now: −$4.04 −$4.04

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$8.87−$4.19
60 days ago −$8.80−$3.49
30 days ago −$6.40−$3.95
7 days ago −$6.36−$4.04
Now −$6.36−$4.04

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$1.64 −$1.99 −21.5%
Mar 2026 −$3.08 −$1.88 +39.0%
Dec 2025 −$2.99 −$2.94 +1.6%
Sept 2025 −$5.07 −$4.64 +8.4%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

6 analysts, Oct 2026
Buy6100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202666
  2. Sep 202666
  3. Aug 202666
  4. Jul 202666

Counts of recommendations published by analysts covering Adicet Bio, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
5.6%
of tradable shares
Days to cover
1.52
at average volume
Short interest, 1 month
+92%
to October 15, 2026
Held by institutions
66%
of shares
Held by insiders
6.4%
of shares
Employees
102
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
ACET+25%−49%−79%−49%−45%−62%
Industry peers (median)−36%−57%−17%−28%−5%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
ACET50%58%33%17%42%27%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
ACET−63%−64%−88%−75%−59%−67%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since January 26, 2018: 100% from February 23, 2018 to November 2, 2026. Getting back needed a 72875% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$3.20 – $11.68
From 52-week high
−72.6%
vs 50-day average
−54.5%
vs 200-day average
−58.3%
Volatility (1 year)
75%
Beta vs S&P 500
2.24

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±8.0%
After a week
5 up, 7 down
typical move ±9.3%
After a month
7 up, 5 down
typical move ±11.3%
Results releasedNext dayS&P 500 next day5 days21 days
August 5, 2026 −13.9% −0.4% −10.3% +2.4%
May 13, 2026 +5.8% +1.4% −2.4% +1.3%
March 12, 2026 −3.5% −2.1% −5.4% −15.0%
November 5, 2025 −1.9% −0.7% −0.4% −22.6%
August 7, 2025 −11.4% +0.7% −7.3% +8.8%
May 6, 2025 −26.4% −0.4% +0.3% +12.6%
March 6, 2025 −9.0% −1.2% −11.3% −27.0%
November 6, 2024 +1.5% +3.3% −13.0% −19.8%
August 13, 2024 +7.9% +2.0% +15.7% +20.5%
May 14, 2024 −2.8% +1.7% +11.8% +0.7%
March 19, 2024 +9.7% +1.5% +14.9% +3.8%
January 24, 2024 −1.6% +0.7% +19.1% −1.6%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$52.8M
Institutions reporting
56
Shares held vs prior quarter
▼ 3.8%
Positions opened / closed
14 / 6

Top buyers and sellers, Q2 2026: 31 institutions bought and 15 sold ; the biggest buyer was Schonfeld Strategic Advisors LLC (+196K shares) and the biggest seller Woodline Partners LP (−313K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
RA Capital Management, L.P. $8.1M 933K 15.3% ▼ 21.1%
Orbimed Advisors LLC $7.3M 845K 13.8% ▼ 17.8%
Franklin Resources Inc $5.4M 627K 10.3% 0.0%
Citadel Advisors LLC $3.7M 433K 7.1% ▲ 13.3%
Vanguard Capital Management LLC $3M 343K 5.6% ▲ 2.0%
Adage Capital Partners Gp, L.L.C. $2.4M 274K 4.5% 0.0%
Renaissance Technologies LLC $2.3M 266K 4.4% ▲ 14.3%
Stonepine Capital Management, LLC $2.1M 246K 4.0% ▲ 10.6%
Alyeska Investment Group, L.P. $1.8M 204K 3.3% 0.0%
Schonfeld Strategic Advisors LLC $1.7M 196K 3.2% New
Carlyle Group Inc. $1.6M 184K 3.0% 0.0%
Nextbio Capital Management LP $1.4M 158K 2.6% 0.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Adicet Bio, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $1.6M 3 trades by 1 insider, last 12 months Insider sales History → $674,847 4 trades by 1 insider · 0% under pre-set plans
Net ▲ $929,087 net buying
Insider Date Trade Shares Price Value
Orbimed Advisors Israel Ii Ltd 10% owner April 8, 2026 Sell 40,416 $6.52 $263,512
Orbimed Advisors Israel Ii Ltd 10% owner April 8, 2026 Sell 32,523 $6.29 $204,570
Orbimed Advisors Israel Ii Ltd 10% owner April 7, 2026 Sell 2,400 $6.38 $15,312
Orbimed Advisors Israel Ii Ltd 10% owner April 7, 2026 Sell 29,319 $6.53 $191,453
Ra Capital Healthcare Fund Lp 10% owner February 20, 2026 Buy 74,751 $7.27 $543,440
Ra Capital Healthcare Fund Lp 10% owner February 19, 2026 Buy 74,268 $7.21 $535,472
Ra Capital Healthcare Fund Lp 10% owner February 18, 2026 Buy 74,577 $7.04 $525,022

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 4, 2026 estimated from the company's past filing pattern, not announced

  • August 5, 2026
  • May 13, 2026
  • March 12, 2026
  • November 5, 2025
  • August 7, 2025
  • May 6, 2025

Recent SEC filings

Data status

When each part of this page on Adicet Bio, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Adicet Bio, Inc. in brief

What does Adicet Bio, Inc. do?
Adicet Bio, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Adicet Bio, Inc.'s stock ticker?
Adicet Bio, Inc. trades under the ticker ACET on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Adicet Bio, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are RA Capital Management, L.P., Orbimed Advisors LLC and Franklin Resources Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Adicet Bio, Inc. stock?
Over the last 12 months, Adicet Bio, Inc.'s directors and officers reported 3 open-market purchases and 4 sales on Form 4. The insider trading page charts every trade.
When is Adicet Bio, Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Adicet Bio, Inc. announces its own schedule.